Full Text AI-93-02 TUBERCULOSIS VACCINE DEVELOPMENT NIH GUIDE, Volume 21, Number 45, December 18, 1992 RFA: AI-93-02 P.T. 34 Keywords: Diagnosis, Medical Infectious Diseases/Agents Immunology Clinical Medicine, General Biomedical Research, Multidiscipl Bioassay National Institute of Allergy and Infectious Diseases Letter of Intent Receipt Date: January 19, 1993 Application Receipt Date: March 18, 1993 PURPOSE The Respiratory Diseases Branch of the Division of Microbiology and Infectious Diseases of the National Institute of Allergy and Infectious Diseases (NIAID) invites applications for basic research that will lead to the development of effective new vaccines for the prevention and control of tuberculosis. At present, a live attenuated strain of Mycobacterium bovis, Bacillus Calmette Guerin (BCG), is the only vaccine available for protecting humans from tuberculosis. Protection elicited by BCG in controlled clinical trials has been variable Applications that feature improvements to BCG will not be considered responsive to this Request for Applications (RFA). However, applications that use BCG components in the development of a novel vaccine(s) are encouraged. HEALTHY PEOPLE 2000 The Public Health Service (PHS) is committed to achieving the health promotion and disease prevention objectives of "Healthy People 2000," a PHS-led national activity for setting priority areas. This RFA, Tuberculosis Vaccine Development, is related to the priority areas immunization and infectious diseases. Potential applicants may obtain a copy of "Healthy People 2000" (Full Report: Stock No. 017-001-00474-0) or "Healthy People 2000" (Summary Report: Stock No. 017-001-00473-1) through the Superintendent of Documents, Government Printing Office, Washington, DC 20402-9325 (telephone 202-783-3238). ELIGIBILITY REQUIREMENTS Domestic and foreign non-profit and for-profit organizations and institutions, governments and their agencies, are eligible to apply. Foreign institutions are not eligible for First Independent Research Support and Transition (FIRST) (R29) awards. Minorities and women are encouraged to apply. Applications from, or involving, minority institutions or women's institutions are encouraged. MECHANISM OF SUPPORT This RFA will use the National Institutes of Health (NIH) individual research project grant (R01), and the FIRST (R29) award. Responsibility for the planning, direction, and execution of the proposed project will be solely that of the applicant. The total project period for applications submitted in response to this RFA may not exceed five years. This RFA is a one-time solicitation. Future recompeting applications will compete with unsolicited applications and will be reviewed according to customary review procedures. FUNDS AVAILABLE The estimated total funds (direct and indirect costs) available for the first year of this program will be $1,000,000. In fiscal year 1993, the NIAID plans to fund at least four R01s and/or R29s. This level of support is dependent on the receipt of a sufficient number of applications of high scientific merit and the availability of funds. RESEARCH OBJECTIVES Background A century ago, tuberculosis (TB) was a leading cause of death in the United States. Through the efforts of researchers, physicians, and public health officials, as well as through improvements in living conditions and the introduction of effective drug therapy, the number of TB cases and deaths in the United States had declined steadily for 40 years. This trend stopped in 1985. The new cases of TB in the U.S. reported to the Centers for Disease Control were 22,517 in 1987, 23,495 in 1989 and 26,283 in 1991. This resurgence of TB is a matter of grave concern. In the United States TB is responsible for an estimated 2000 deaths annually. Approximately 10 million persons in the United States are presently infected with the TB organism and have the potential to develop clinical TB (active disease) at some time in their lives. Globally, TB is an even more serious threat. An estimated 8 million new TB cases and 2.9 million TB deaths occur each year . (Science, Vol. 21, p1055-1064, Aug. 21, 1992). The recent rise in tuberculosis cases reported in the United States and elsewhere is attributed, at least in part, to the heightened susceptibility to TB infections of HIV-positive persons. Other factors, including intravenous drug abuse, the increased influx of immigrants from less developed nations, and poor socio-economic status also contributed to this rise. The concern of health officials about the number of cases is intensified by the recent growth in the number of isolates of multi-drug-resistant M. tuberculosis (MDRTB). The background to these developments is documented in publications of the Centers for Disease Control (see, for instance, Morbidity and Mortality Weekly Reports, March 1, 1991, Vol. 40, No. 8 and June 19, 1992, Vol. 41, No. RR-11). The case fatality rate for TB resistant to two or more drugs (MRDTB) is 40 to 60 percent, and the overall costs for treatment of these cases is five times higher than for drug-susceptible TB patients. While treatment of drug-responsive tuberculosis infections is generally effective, the treatment regimen is lengthy, and many patients do not complete therapy. This interruption in treatment not only increases the likelihood of relapse but also is believed to promote the emergence of drug-resistant Mycobacterium tuberculosis strains. These problems continue, mainly because of the lack of a safe and efficacious vaccine to control tuberculosis. An effective vaccine will likely induce responses in the host similar to those induced by natural infection. Ordinarily, persons are infected after exposure to an infected patient. Tuberculosis is transmitted through airborne droplets containing the bacillus. The transmission is difficult to control through behavior modification for the principal risk factor is breathing. Inhaled bacilli are typically ingested by phagocytes in the lung where they may either be killed or grow to a limited extent. Usually, cell-mediated immunity develops with a few weeks and the infection is controlled. A clear understanding of this immunity and of other aspects of the host response to natural infection could serve as the basis for the development of a safe, effective vaccine. Identification of protective antigens and epitopes could provide insight into both pathogenic mechanisms and the immunologic responses evoked in the infected host. At present, a live attenuated strain of Mycobacterium bovis, Bacillus Calmette-Guerin [BCG], is the only vaccine available for protection of humans from tuberculosis. Protection elicited by BCG in controlled clinical trials has been variable; therefore, the efficacy of this vaccine has been seriously questioned. Moreover, there is no single BCG vaccine. It is produced at dozens of sites located throughout the world, each site maintaining its individual seed strain. This potential for diversity is a cause for concern among some health care personnel. Because BCG is a live vaccine, it may be unsuitable for HIV-positive individuals; it is contraindicated for AIDS patients. A new, more effective vaccine that prevents primary and/or reactivation tuberculosis would be of great benefit. Research Objectives The long term goal of this initiative is to promote efforts to develop new, more effective vaccines, not based on BCG, to prevent and control tuberculosis. This will require innovative research approaches to develop candidate vaccine preparations that will elicit appropriate and protective functional responses. In order to achieve this objective, a focused effort on the basic biology of the mycobacterium and an understanding of the host response to natural infection is needed. Consistent with this, applicants are encouraged to develop innovative projects that address any of, though not be limited to, the following areas: o Identification and characterization of components of M. tuberculosis that are immunogenic. o Identification and characterization of immunogens that elicit responses by the host during natural infection. o Isolation and characterization of relevant immunogen-coding sequences and their products. o Characterization of the host response to natural infection and definition of the correlates of protective immunity. Should an applicant have access to, or have already identified and prepared a novel candidate vaccine, this RFA would also encourage research in the area of: o Enhancement of the immunogenicity of candidate vaccine immunogens. o Development of animal model(s) for testing candidate vaccine immunogens. The areas outlined are not intended to be all-inclusive nor are they all required. SPECIAL REQUIREMENTS NIAID program staff will organize annual meetings that Principal Investigators and other key members (as designated by the Principal Investigators) of the projects are encouraged to attend to discuss progress. This will facilitate overall program planning and development, evaluation of the feasibility of planned approaches, and will promote productive interactions among the awardees. Funds for travel to these meetings may be included in the budget. NIAID program staff will also ensure and arrange for the participation in these meetings of investigators from other relevant NIAID-supported tuberculosis research projects, if appropriate, in order to further promote fruitful interactions. STUDY POPULATIONS SPECIAL INSTRUCTIONS TO APPLICANTS REGARDING IMPLEMENTATION OF NIH POLICIES CONCERNING INCLUSION OF WOMEN AND MINORITIES IN CLINICAL RESEARCH STUDY POPULATIONS NIH policy is that applicants for NIH clinical research grants and cooperative agreements will be required to include minorities and women in study populations so that research findings can be of benefit to all persons at risk of the disease, disorder or condition under study; special emphasis should be placed on the need for inclusion of minorities and women in studies of diseases, disorders and conditions which disproportionately affect them. This policy is intended to apply to males and females of all ages. If women or minorities are excluded or inadequately represented in clinical research, particularly in proposed population-based studies, a clear compelling rationale should be provided. The composition of the proposed study populations must be described in terms of gender and racial/ethnic group, together with a rationale for its choice. In addition, gender and racial/ethnic issues should be addressed in developing a research design and sample size appropriate for the scientific objectives of the study. This information should be included in the form PHS 398 (rev. 9/91) in Sections 1-4 of the Research Plan AND summarized in Section 5, Human Subjects. Applicants are urged to assess carefully the feasibility of including the broadest possible representation of minority groups. However, NIH recognizes that it may not be feasible or appropriate in all research projects to include representation of the full array of United States racial/ethnic minority populations (i.e., Native Americans including American Indians or Alaskan Natives, Asian/Pacific Islanders, Blacks, Hispanics). The rationale for studies on single minority population groups should be provided. For the purpose of this policy, clinical research includes human biomedical and behavioral studies of etiology, epidemiology, prevention (and preventive strategies), diagnosis, or treatment of diseases, disorders or conditions, including but not limited to clinical trials. The usual NIH policies concerning research on human subjects also apply. Basic research or clinical studies in which human tissues cannot be identified or linked to individuals are excluded. However, every effort should be made to include human tissues from women and racial/ethnic minorities when it is important to apply the results of the study broadly, and this should be addressed by applicants. For foreign awards, the policy on inclusion of women applies fully; since the definition of minority differs in other countries, the applicant must discuss the relevance of research involving foreign populations groups to the United States' populations, including minorities. If the required information is not contained within the application, the application will be returned. Peer reviewers will address specifically whether the research plan in the application conforms to these policies. If the representation of women or minorities in a study design is inadequate to answer the scientific question(s) addressed AND the justification for the selected study population is inadequate, it will be considered a scientific weakness or deficiency in the study design and will be reflected in assigning the priority score to the application. All applications for clinical research submitted to NIH are required to address these policies. NIH funding components will not support applications that do not comply. LETTER OF INTENT Prospective applicants are asked to submit, by January 19, 1993, a letter of intent that includes a descriptive title of the proposed research, the name, address and telephone number of the Principal Investigator, the identities of other key personnel and the participating institution, and the number and title of the RFA. Although a letter of intent is not required, is not binding, and does not enter into the review of subsequent applications, the information it contains allows NIAID staff to estimate the potential review workload and avoid conflict of interest in the review. The letter of intent is to be sent to Dr. Olivia Preble at the address listed under INQUIRIES. APPLICATION PROCEDURES The research grant application form PHS 398 (rev. 9/91) is to be used in applying for these grants. These forms are available at most institutional offices for sponsored research or business offices and from the Office of Grants Inquiries, Division of Research Grants, National Institutes of Health, Westwood Building, Room 449, Bethesda, MD 20892, telephone (301) 496-7441. The deadline for receipt of applications in response to this RFA is March 18, 1993. Applications for FIRST (R29) awards must include at least three sealed letters of reference attached to the face page of the original application. FIRST award applications submitted without the required number of reference letters will be considered incomplete and will be returned without review. Applicants from institutions that have a General Clinical Research Center (GCRC) funded by the NIH National Center of Research Resources may wish to identify the Center as a resource for conducting the proposed research. If so, a letter of agreement from the GCRC Program Director must be included in the application material. The RFA label available in the application form must be affixed to the bottom of the face page. Failure to use this label could result in delayed processing of the application such that it may not reach the review committee in time for review. In addition, the RFA title "Tuberculosis Vaccine Development" and number (AI-93-02) must be typed on line 2a of the face page of the application and the "Yes" box marked. Submit a signed, typewritten original of the application including the Checklist, and three signed, exact single-sided photocopies, in one package, to: Division of Research Grants National Institutes of Health Westwood Building, Room 240 Bethesda, MD 20892** At the time of submission to the Division of Research Grants (DRG), two additional exact copies must be sent to Dr. Olivia Preble at the address listed under INQUIRIES. Applications received after the deadline will be returned without review. Alternatively, the late applicant will be contacted and given the choice of having the application returned or of having it submitted for review in competitition with unsolicited applications at the next DRG review cycle. The DRG will not accept any application in response to this announcement that is essentially the same as one currently pending initial review, unless the applicant withdraws the pending application. The DRG will not accept any application that is essentially the same as one already reviewed. This does not exclude the submission of substantial revisions of application already reviewed. These applications must, however, include an introduction addressing the previous critique. REVIEW CONSIDERATIONS Upon receipt, applications and supporting material will be reviewed by the DRG for completeness and by NIAID staff for responsiveness to the RFA. Incomplete applications will be returned without further consideration. If the application is complete but not responsive to the RFA, NIAID staff will contact the applicant and present the same options for handling the application as in late applications, above. Applications may be triaged by an NIAID peer review group on the basis of relative competitiveness among the applications responsive to the RFA. The NIH will withdraw from further competition those applications judged to be non-competitive for award and notify the applicant Principal Investigator and institutional official. Those applications that are complete and responsive will be evaluated in accordance with the criteria stated below for scientific/technical merit by an appropriate review committee convened by the NIAID. The second level of review will be provided by the National Advisory Allergy and Infectious Diseases Council. Review criteria for applications received in response to an RFA are generally the same as those for unsolicited applications, namely: o Scientific, technical, or medical significance and originality of the proposed research. o Appropriateness and adequacy of the experimental approach and methodology proposed to accomplish the research. o Qualification and research experience of the Principal investigator and staff, particularly, but not exclusively, in the area of the proposed research. o Availability of resources to carry out the proposed research. o Appropriateness of the proposed budget and duration of the project in relation to the proposed research. AWARD CRITERIA The anticipated date of award is September 30, 1993. The primary criterion for award is the scientific and technical merit of the application as judged by peer reviewers and reflected in the priority score. Additional award criteria are the availability of funds and the receipt of a sufficient number of scientifically meritorious applications that are responsive to the RFA. INQUIRIES Written and telephone inquiries concerning this RFA are encouraged. The opportunity to clarify issues or questions from potential applicants is welcome. Direct inquiries regarding programmatic issues to: Dr. John Foulds Tuberculosis Program Officer Respiratory Diseases Branch Division of Microbiology and Infectious Diseases National Institute of Allergy and Infectious Diseases Solar Building, Room 3A31 Bethesda, MD 20892 Telephone: (301) 496-5305 FAX: (301) 496-8030 Direct inquiries regarding the review of applications to: Dr. Olivia Preble Chief, Microbiology and Immunology Review Section Scientific Review Branch Division of Extramural Activities National Institute of Allergy and Infectious Diseases Solar Building, Room 4C20 Bethesda, MD 20892 Telephone: (301) 496-8208 FAX: (301) 402-2638 Direct inquiries regarding fiscal matters to: Mr. Todd Ball Chief, Microbiology and Infectious Diseases Grants Management Section Grants Management Branch Division of Extramural Activities National Institute of Allergy and Infectious Diseases Solar Bldg., Room 4B35 Bethesda, MD 20892 Telephone: (301) 496-7075 The mailing address for sending applications, letters of intent, or other correspondence to NIAID staff in the solar building is the central mailing address for the NIH. Applicants who use express mail or a courier service are advised to follow the carrier's requirements for showing a street address. The address for the solar building is: 6003 Executive Boulevard Rockville, MD 20852 SCHEDULE Letter of intent date: January 19, 1993 Application receipt date: March 18, 1993 Scientific review date: July 1993 Advisory Council date: September 1993 Award date: September 30, 1993 AUTHORITY AND REGULATIONS This program is supported under authorization of the Public Health Service Act, Sec. 301 (c), Public Law 78-410, as amended. The Catalogue of Federal Domestic Assistance Citation is Sec. 93.856, Microbiology and Infectious Diseases Research. Awards will be administered under PHS grants policies and Federal Regulations 42 CFR Part 52 and 45 CFR Part 74. This program is not subject to the intergovernmental review requirements of Executive Order 12372 or Health Systems review. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |